ID: ALA5279560

Max Phase: Preclinical

Molecular Formula: C14H14N2O4S

Molecular Weight: 306.34

Associated Items:

Representations

Canonical SMILES:  O=C(c1sc(-c2ccccc2O)nc1O)N1CCCCO1

Standard InChI:  InChI=1S/C14H14N2O4S/c17-10-6-2-1-5-9(10)13-15-12(18)11(21-13)14(19)16-7-3-4-8-20-16/h1-2,5-6,17-18H,3-4,7-8H2

Standard InChI Key:  BAJJMCUHUGXFST-UHFFFAOYSA-N

Associated Targets(Human)

Transient receptor potential cation channel subfamily M member 8 1168 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 306.34Molecular Weight (Monoisotopic): 306.0674AlogP: 2.39#Rotatable Bonds: 2
Polar Surface Area: 82.89Molecular Species: ACIDHBA: 6HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.61CX Basic pKa: CX LogP: 3.28CX LogD: 1.67
Aromatic Rings: 2Heavy Atoms: 21QED Weighted: 0.89Np Likeness Score: -0.91

References

1. Bianchini G, Tomassetti M, Lillini S, Sirico A, Bovolenta S, Za L, Liberati C, Novelli R, Aramini A..  (2021)  Discovery of Novel TRPM8 Blockers Suitable for the Treatment of Somatic and Ocular Painful Conditions: A Journey through pKa and LogD Modulation.,  64  (22): [PMID:34762442] [10.1021/acs.jmedchem.1c01647]

Source